MptpB-IN-3

MptpB-IN-3 (Compound 4) inhibits purified recombinant human PTP1B with an IC₅₀ of 65.61 μM, demonstrating 345-fold selectivity for Mycobacterium tuberculosis MptpB over the human phosphatase^[1].
MptpB-IN-3 inhibits the growth of drug-sensitive Mycobacterium tuberculosis H37Rv with a MIC of 1.94 μg/mL^[1].
MptpB-IN-3 inhibits the growth of multi-drug-resistant Mycobacterium tuberculosis strains 13946 and 14862 with MICs of 3.80 μg/mL and 4.60 μg/mL, respectively, but is inactive against a pretomanid-resistant strain (MIC >32 μg/mL)^[1].
MptpB-IN-3 (0.26-64 μg/mL; 48 h) exhibits no cytotoxicity against Vero and J774A.1 macrophage cells (IC₅₀ >64 μg/mL) and low cytotoxicity against HepG2 cells (IC₅₀ = 55.92 μg/mL)^[1].
MptpB-IN-3 (1-10 μg/mL) reduces Mycobacterium tuberculosis burden in infected J774A.1 macrophages in a dose-dependent manner, and exhibits greater potency than Rifampicin and PA-824 at equivalent doses^[1].
MptpB-IN-3 (5-20 μM; 3 h) specifically restores Erk1/2 and p38 phosphorylation in IFN-γ-stimulated Raw264.7 cells overexpressing wild-type Mycobacterium tuberculosis MptpB, reversing MptpB-mediated suppression of the MAPK pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.